Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001628280-26-023937
Filing Date
2026-04-06
Accepted
2026-04-06 17:15:55
Documents
22
Period of Report
2026-04-06

Document Format Files

Seq Description Document Type Size
1 PRE 14A skye_20260406xproxyxprelim.htm PRE 14A 782695
2 capvsnetincomechartdatam.jpg GRAPHIC 52898
3 capvstschart.jpg GRAPHIC 50523
4 date.gif GRAPHIC 3431
5 image_0.jpg GRAPHIC 13735
6 image_1.jpg GRAPHIC 201685
7 image_11.jpg GRAPHIC 23303
8 image_12.jpg GRAPHIC 30677
9 image_13.jpg GRAPHIC 25471
10 image_14.jpg GRAPHIC 24319
11 image_15.jpg GRAPHIC 25161
12 image_16.jpg GRAPHIC 30356
13 image_19.jpg GRAPHIC 25941
14 image_20.jpg GRAPHIC 25815
15 image_3.jpg GRAPHIC 17366
16 internet.gif GRAPHIC 5534
17 location.gif GRAPHIC 3253
18 ml.gif GRAPHIC 2411
19 phone.gif GRAPHIC 1519
20 proxycardpage1-x.jpg GRAPHIC 150068
21 proxycardpage2-x.jpg GRAPHIC 105197
22 time.gif GRAPHIC 3373
  Complete submission text file 0001628280-26-023937.txt   1915808
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

EIN.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-42009 | Film No.: 26842145
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)